Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV).

Jesús Troya García Roberto Pedrero-Tomé Luis Buzón MartínCarlos Dueñasnull On Behalf Of The Spade Study Group

Published in: Journal of clinical medicine (2023)

These models represent a proof of concept that could become a valuable tool for clinicians to predict the effects of DTG plus 3TC on immunological responses prior to the switch in undetectable pre-treated PLWHIV with immune dysfunction. The main predictors for immunological failure were late HIV diagnosis, stage of AIDS, and current age over 50 years. In contrast, starting with a normalized immune status was detected as stimulating or conducive to DTG plus 3TC treatment success.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
magnetic resonance
hepatitis c virus
hiv testing
oxidative stress
palliative care
computed tomography
magnetic resonance imaging
men who have sex with men
combination therapy